24223-25-4 Usage
General Description
1-({2-nitrophenyl}carbonyl)-1,2,3,4-tetrahydroquinoline is a chemical compound that belongs to the class of quinoline derivatives. It has a tetrahydroquinoline backbone with a 2-nitrophenylcarbonyl group attached at the 1 position. 1-({2-nitrophenyl}carbonyl)-1,2,3,4-tetrahydroquinoline has potential applications in the pharmaceutical industry, particularly in the development of new drugs. The presence of the nitrophenyl group makes it a useful building block for the synthesis of various biologically active compounds. Additionally, its quinoline backbone gives it the potential to act as an anti-malarial or anti-microbial agent. Overall, 1-({2-nitrophenyl}carbonyl)-1,2,3,4-tetrahydroquinoline is a versatile chemical with various potential applications in drug development and other fields.
Check Digit Verification of cas no
The CAS Registry Mumber 24223-25-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,4,2,2 and 3 respectively; the second part has 2 digits, 2 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 24223-25:
(7*2)+(6*4)+(5*2)+(4*2)+(3*3)+(2*2)+(1*5)=74
74 % 10 = 4
So 24223-25-4 is a valid CAS Registry Number.
24223-25-4Relevant articles and documents
Orally active, nonpeptide vasopressin V2 receptor antagonists: A novel series of 1-[4-(benzoylamino)benzoyl]-2,3,4,5-tetrahydro-1H-benzazepines and related compounds
Ogawa, Hidenori,Yamashita, Hiroshi,Kondo, Kazumi,Yamamura, Yoshitaka,Miyamoto, Hisashi,Kan, Keizo,Kitano, Kazuyoshi,Tanaka, Michinori,Nakaya, Kenji,Nakamura, Shigeki,Mori, Toyoki,Tominaga, Michiaki,Yabuuchi, Youichi
, p. 3547 - 3555 (2007/10/03)
This paper describes a novel series of nonpeptide vasopressin V2 receptor antagonists. It has been demonstrated that the 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-benzazepines and 1-[4- (benzoylamino)benzoyl]-2,3,4,5-1H-1,5-benzodiazepines show a high affinity for V2 (and V(1a)) receptors. Among the 1-[4-(benzoylamino)benzoyl]-2,3,4,5- 1H-benzazepine series, compounds with an alkylamino group on the benzazepine ring have been shown to have oral activity. A lipophilic group at the ortho position on the terminal benzoyl ring is important for both high V2 receptor affinity and oral activity. On the basis of these favorable properties, clinical testing of 31b has begun for use as an oral and iv aquaretic agent.
